Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · IEX Real-Time Price · USD
5.00
-0.63 (-11.19%)
At close: May 17, 2024, 4:00 PM
5.01
+0.01 (0.20%)
After-hours: May 17, 2024, 7:59 PM EDT
Treace Medical Concepts Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TMCI stock have an average target of 9.67, with a low estimate of 5.50 and a high estimate of 25. The average target predicts an increase of 93.40% from the current stock price of 5.00.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for TMCI stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy → Hold Downgrades $16 → $6.5 | Strong Buy → Hold | Downgrades | $16 → $6.5 | +30.00% | May 16, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $15 → $5.5 | Buy → Hold | Downgrades | $15 → $5.5 | +10.00% | May 8, 2024 |
| UBS | UBS | Strong Buy Maintains $17 → $16 | Strong Buy | Maintains | $17 → $16 | +220.00% | May 8, 2024 |
| Truist Securities | Truist Securities | Strong Buy → Hold Downgrades $17 → $7 | Strong Buy → Hold | Downgrades | $17 → $7 | +40.00% | May 8, 2024 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $15 → $8 | Buy → Hold | Downgrades | $15 → $8 | +60.00% | May 8, 2024 |
Financial Forecast
Revenue This Year
227.27M
from 187.12M
Increased by 21.46%
Revenue Next Year
268.35M
from 227.27M
Increased by 18.08%
EPS This Year
-0.95
from -0.81
EPS Next Year
-0.83
from -0.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 234.8M | 281.9M | 339.5M | 408.9M | 492.5M |
| Avg | 227.3M | 268.4M | 313.4M | 397.2M | 478.4M |
| Low | 217.9M | 249.7M | 287.4M | 381.6M | 459.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.5% | 24.1% | 26.5% | 30.5% | 24.0% |
| Avg | 21.5% | 18.1% | 16.8% | 26.7% | 20.4% |
| Low | 16.5% | 9.9% | 7.1% | 21.8% | 15.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.88 | -0.72 | -0.64 | -0.37 | -0.11 |
| Avg | -0.95 | -0.83 | -0.79 | -0.36 | -0.10 |
| Low | -0.99 | -1.01 | -1.10 | -0.34 | -0.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.